Evidence map›Paper›PMID 41733424›Full record

ArticleMolecular cancer research : MCR2026

Epigenetic Atlas of Bladder Cancer Reveals Master Transcription Factors and Risk-Associated Regulatory Elements in Luminal and Basal-Squamous Molecular Subtypes.

Elio Adib, Amin H Nassar, Sarah Abou Alaiwi, Sylvan C Baca, Timothy Hanlon, Elias Bou Farhat, Yan Tang, Rosario I Corona, Ji-Heui Seo, Talal El Zarif and 11 more

Abstract read
In one paragraph

Article in Molecular cancer research : MCR, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Elio Adib *Department of Radiation Oncology, Brigham and Women's Hospital, Boston, Massachusetts.ORCID 0000-0003-0594-7976
Amin H Nassar *Department of Hematology/Oncology, Yale New Haven Hospital, New Haven, Connecticut.ORCID 0000-0002-8084-9105
Sarah Abou Alaiwi *Department of Cardiology, Yale New Haven Hospital, New Haven, Connecticut.ORCID 0000-0002-7073-3432
Sylvan C BacaDepartment of Medicine, Brigham and Women's Hospital, Boston, Massachusetts.ORCID 0000-0002-4087-8606
Timothy HanlonDepartment of Radiation Oncology, Brigham and Women's Hospital, Boston, Massachusetts.ORCID 0000-0003-0676-942X
Elias Bou FarhatDepartment of Medicine, Brigham and Women's Hospital, Boston, Massachusetts.ORCID 0009-0001-0063-0518
Yan TangDepartment of Medicine, Brigham and Women's Hospital, Boston, Massachusetts.ORCID 0000-0002-6223-8423
Rosario I CoronaDepartment of Human Genetics, University of California, Los Angeles, Los Angeles, California.ORCID 0000-0003-0470-4446
Ji-Heui SeoDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.ORCID 0000-0002-7280-3334
Talal El ZarifDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.ORCID 0000-0002-4507-2396
Marcos A S FonsecaDepartment of Molecular and Cell Biology, University of California Berkeley, Berkeley, California.ORCID 0000-0002-6172-3558
Andres M AcostaDepartment of Pathology, Indiana University Health University Hospital, Indianapolis, Indiana.ORCID 0000-0001-8817-6331
Magdalena LoskoDepartment of Medicine, Brigham and Women's Hospital, Boston, Massachusetts.ORCID 0000-0001-9511-1747
Ziwei ZhangDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.ORCID 0000-0002-0246-6619
Michelle S HirschDepartment of Pathology, Brigham and Women's Hospital, Boston, Massachusetts.ORCID 0000-0002-8767-8564
Alexander GusevDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.ORCID 0000-0002-7980-4620
Kate LawrensonDepartment of Obstetrics and Gynecology, University of Texas Health San Antonio, San Antonio, Texas.ORCID 0000-0002-6469-2515
Kent W MouwDepartment of Radiation Oncology, Brigham and Women's Hospital, Boston, Massachusetts.ORCID 0000-0001-7939-7343
Toni K Choueiri *Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.ORCID 0000-0002-9201-3217
David J Kwiatkowski *Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts.ORCID 0000-0002-5668-5219
Matthew L Freedman *Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.ORCID 0000-0002-0151-1238

Funding

VectorP30CA006516 · NCI · DANA-FARBER CANCER INSTITUTE · PI A. Heather Eliassen · 1985 to 2026
$330.6M
Treating the P13-Kinase/AKTP50CA101942 · NCI · BETH ISRAEL DEACONESS MEDICAL CENTER · PI Wanling Xie · 2003 to 2026
$53.4M
Molecular Determinants of Response and Resistance to EZH2 and PARP inhibition in Prostate CancerP50CA272390 · NCI · DANA-FARBER CANCER INST · PI Steven P. Balk, Himisha Beltran · 2023 to 2026
$12.0M
Elucidation of the genetic mechanisms driving prostate tumorigenesis through integrative computational and functional approachesR01CA251555 · NCI · DANA-FARBER CANCER INST · PI FREEDMAN, MATTHEW L, PASANIUC, BOGDAN · 2021 to 2025
$3.4M
Elucidating prostate cancer risk mechanisms through large-scale cistrome wide association studiesR01CA262577 · NCI · DANA-FARBER CANCER INST · PI FREEDMAN, MATTHEW L, GIMELBRANT, ALEXANDER · 2022 to 2025
$3.3M
Dana-Farber Cancer Institute (DFCI) Presidential Initiatives FundH. L. Snyder Medical Foundation (HLSMF)National Institutes of Health (NIH) P50CA272390National Institutes of Health (NIH) R01CA251555National Institutes of Health (NIH) R01CA262577NCI NIH HHS P30 CA006516NCI NIH HHS P50 CA101942NCI NIH HHS P50 CA272390NCI NIH HHS R01 CA251555NCI NIH HHS R01 CA262577The Cutler Family Fund for Prevention and Early DetectionThe Donahue Family Fund
6 · The paper itself

Abstract

We generated 64 epigenomic datasets using chromatin immunoprecipitation with sequencing and assay for transposase-accessible chromatin sequencing profiling on 28 fresh bladder cancer specimens of luminal and basal-squamous expression subtypes. An integrated analysis of core regulatory circuitry, enhancer activity, and transcription factor (TF) expression specificity nominated 23 luminal-specific and 14 basal-squamous-specific candidate master TFs (MTF), including established regulators like FOXA1, PPARG, and GATA3 for luminal bladder cancer and TP63 for basal-squamous bladder cancer, as well as new basal-squamous MTF candidates, SNAI2 and CEBPB. GRHL2, a regulator of subtype differentiation, was identified as a common MTF to luminal and basal-squamous bladder cancers. Cis-regulatory elements were enriched up to 80-fold for bladder cancer risk variants. Keratinization pathways were enriched in genetically determined basal-squamous sites, whereas carcinogen glucuronidation pathways were enriched in luminal sites. Integrating germline variation and epigenomics through a cistrome-wide association study identified a new bladder cancer risk locus upstream of SPINK1 and linked 10 of 19 bladder cancer risk loci to regulatory elements from a 350,000-sample genome-wide association study. IMPLICATIONS: Overall, this integrative computational analysis provides comprehensive insights into the epigenomic underpinnings of bladder cancer subtypes, nominates candidate master regulators of cellular identity for future experimental validation, and reveals how regulatory elements harboring inherited germline variation may contribute to bladder cancer risk and biology.

Indexed as

Transcription FactorsUrinary Bladder NeoplasmsEpigenesis, GeneticEpigenomicsGene Expression Regulation, NeoplasticHumansTranscription Factors

Identifiers

PMID41733424
PMCPMC13682644

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.